Corneal endothelial deposits in children positive for human immunodeficiency virus receiving rifabutin prophylaxis for Mycobacterium avium complex bacteremia

American Journal of Ophthalmology

Volumn 127, Issue 2, 1999, Pages 164-169

  Smith, Janine A ^a   Mueller, Brigitta U ^b   Nussenblatt, Robert B ^a   Whitcup, Scott M ^a  

^a NATIONAL EYE INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; RIFABUTIN;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CORNEA DISEASE; CORNEA ENDOTHELIUM; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; LYMPHOCYTE COUNT; MALE; MYCOBACTERIOSIS; MYCOBACTERIUM INTRACELLULARE AVIUM; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; UVEITIS;

ADOLESCENT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; BACTEREMIA; CELL COUNT; CHILD; CHILD, PRESCHOOL; CORNEAL DISEASES; ENDOTHELIUM, CORNEAL; FEMALE; HIV SEROPOSITIVITY; HUMANS; MALE; MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION; PROSPECTIVE STUDIES; RIFABUTIN; VISUAL ACUITY;

EID: 0033005589     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9394(98)00310-9     Document Type: Article

References (26)

1. Mines J.A., Kaplan H.J. Acquired immunodeficiency syndrome (AIDS) the disease and its ocular manifestations . Int Ophthalmol Clin. 28:1986;73.
2. Nightingale S.D., Byrd L.T., Southern P.M., Jokusch J.D., Cal S.X., Wynn B.A. Incidence of Mycobacterium avium intracellulare complex bacteremia in human immunodeficiency virus-positive patients. J Infect Dis. 165:1992;1082-1085.
3. Lewis L.L., Butler K.M., Husson R.N., et al. Defining the population of human immunodeficiency virus-infected children at risk for Mycobacterium avium-intracellulare infection. J Pediatr. 121:1992;677-683.
4. Nightingale S.D., Camerson D.W., Gordin F.M., et al. Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS. N Engl J Med. 329:1993;828-833.
5. Siegal F.P., Eilbott D., Burger H., et al. Dose-limiting toxicity of rifabutin in AIDS-related complex syndrome of arthralgia/arthritis . AIDS. 4:1990;433-441.
6. Tseng A.L., Walmsley S.L. Rifabutin associated uveitis. Ann Pharmacother. 29:1995;1149-1155.
7. Griffith D.E., Brown B.A., Girard W.M., Wallace R.J. Jr. Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium complex lung disease. Clin Infect Dis. 21:1995;594-598.
8. Frau E., Gregoire-Cassoux N., Hannouche D., et al. Uveite a hypopion chez des patients presentant un syndrome d'immunodeficience acquire et traites par rifabutine. J Fr Ophtalmol. 8:1995;435-438.
9. Rifai A., Peyman G.A., Daun M., et al. Rifabutin-associated uveitis during prophylaxis for Mycobacterium avium complex infection. Arch Ophthalmol. 113:1995;707.
10. Karbassi M., Nilcou S. Acute uveitis in patients with acquired immunodeficiency syndrome receiving prophylactic rifabutin. Arch Ophthalmol. 113:1995;699-701.
11. Ulirsch R.C., Jaffe E.S. Sjögren's syndrome-like illness associated with the acquired immunodeficiency syndrome-related complex. Hum Pathol. 18:1987;1063-1068.
12. Walter K.A., Coulter V.L., Palay D.A., et al. Corneal endothelial deposits in patients with cytomegalovirus retinitis. Am J Ophthalmol. 121:1996;391-396.
13. Yee R.W., Matsuda M., Schults R.O., Edelhauser H.F. Changes in the normal corneal endothelial cellular pattern as a function of age. Curr Eye Res. 4:1985;571-578.
14. Jones N.P. Fuchs heterochromic uveitis an update . Surv Ophthalmol. 37:1993;253-272.
15. Fraunfelder FT. Drug induced ocular side effects, 4th ed. Baltimore: Williams & Wilkins, 1996:77-78, 219.
16. Physicians' Desk Reference. Montvale, NJ: Medical Economics, 1995:1893-1895.
17. O'Brien R.J., Lyle M.A., Snider D.E. Jr. Rifabutin (ansamycin LM 427) a new rifamysin-S derivative for the treatment of mycobacterial diseases . Rev Infect Dis. 9:1987;519-530.
18. Jacobs D.S., Pilliero P.J., Kuperwaser M.G., et al. Acute uveitis associated with rifabutin use in patients with HIV infection. Am J Ophthalmol. 118:1994;716-722.
19. Saran B.R., Maguire A.M., Nichols C., et al. Hypopyon uveitis in patients with AIDS treated for systemic Mycobacterium avium complex infection with rifabutin. Arch Ophthalmol. 112:1994;1159-1165.
20. Whitcup S.M. Ocular manifestations of AIDS. JAMA. 275:1996;142-144.
21. Frank M.O., Graham M.B., Wispelway B. Rifabutin prophylaxis and uveitis. N Engl J Med. 330:1994;1315-1316.
22. Skinner M.H., Blaschke T.F. Clinical pharmacokinetics of rifabutin. Clin Pharmacokinet. 28:1995;115-123.
23. Levin R., Bolinger D., Burger H., et al. Treatment of nontuberculous mycobacterial infections in pediatric patients. Clin Pharmacol. 7:1988;545-551.
24. Lewis L., Jacobsen F., Mueller B., et al. A phaseI/II assessment of oral rifabutin suspension for the prophylaxis of Mycobacterium avium complex in HIV-infected children. Abstracts of the First National Conference on Human Retroviruses and Related Infections. 1993;107 American Society of Microbiology, Washington, DC.
25. Griffith D.E., Brown B.A., Girard W.M., Wallace R.J. Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium complex lung disease. Clin Infect Dis. 21:1995;594-598.
26. Mandigo K., Hogg R.S., Phillips P., et al. Pattern of utilization of rifabutin for prophylaxis of Mycobacterium avium complex among patients with advanced human immunodeficiency virus disease in a community setting. Tuber Lung Dis. 77:1996;233-238.